Table 1.
Clinical and laboratory characteristics of 139 PCR-confirmed and hospitalized COVID-19 patients.
| Clinical and laboratory characteristics of study cohort (N = 139). | No. Available | Value |
|---|---|---|
| Age (yr), median [IQR] | 139 | 65 [54–77] |
| Gender - N (%) | 139 | |
| Female | 48 (34) | |
| Male | 91 (65) | |
| BMI (kg/m2), median [IQR] | 135 | 27,2 [23–48] |
| Overweight (BMI ≥ 25) | 52 (38) | |
| Obese (BMI ≥ 30) | 41 (30) | |
| Smoking status, N (%) | ||
| Never | 97 (70) | |
| Former | 35 (25) | |
| Current | 7 (5) | |
| Number of coexisting conditions, N (%) | 139 | |
| 0 | 5 (4) | |
| 1 | 19 (14) | |
| 2 | 19 (14) | |
| >2 | 96 (69) | |
| Coexisting conditions, N (%) | 139 | |
| Hypertension | 90 (65) | |
| Diabetes | 50 (36) | |
| Hypercholesterolemia | 54 (39) | |
| Obstructive sleep apnea syndrome | 11 (8) | |
| Obstructive lung diseases | 25 (18) | |
| Coronary artery disease | 19 (14) | |
| Congestive heart failure | 23 (16) | |
| Atrial fibrillation | 14 (10) | |
| Chronic liver disease | 4 (3) | |
| Chronic kidney disease | 31 (22) | |
| Malign neoplasm | 9 (6) | |
| Immune suppression | 25 (18) | |
| Neurological nonvascular | 12 (9) | |
| Stroke | 8 (6) | |
| Days with symptoms before inclusion, median [IQR] | 131 | 8 [6–12] |
| Days of hospitalization before inclusion, median [IQR] | 139 | 1 [1–2] |
| COVID-19 medical therapy before inclusion | 139 | 108 (78) |
| Hydroxychloroquine | 9 (6) | |
| Dexamethasone | 99 (71) | |
| Severity of COVID-19 (worst WHO score) | 139 | |
| Median WHO score [IQR] | 4 [4–6] | |
| With score > 5 (severe disease), N (%) | 42 (30) | |
| cHIS score at inclusion | 134 | |
| Median [IQR] | 2 [1–2] | |
| With cHIS score ≧2, N (%) | 74 (55) | |
| Plasma zinc (Normal range: [80–120 µg/dL]) | 139 | |
| Median level [IQR] | 57 [45–67] | |
| With zinc deficiency, N (%) | 133 (96) |
Abreviations:IQR = interquartile range, CI = confidence interval, OR = odds ratio.